Adding aprepitant to palonosetron does not decrease carboplatin-induced nausea and vomiting in patients with gynecologic cancer

BACKGROUND: Recently, aprepitant has been recommended in carboplatin-based regimens, but there are limited reports on the efficacy of administering aprepitant, palonosetron, and dexamethasone (DEX) in carboplatin-containing regimens. Moreover, because aprepitant is an expensive drug, confirming its...

Descripción completa

Detalles Bibliográficos
Autores principales: Watanabe, Yuko, Saito, Yoshitaka, Mitamura, Takashi, Takekuma, Yoh, Sugawara, Mitsuru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8168009/
https://www.ncbi.nlm.nih.gov/pubmed/34059157
http://dx.doi.org/10.1186/s40780-021-00204-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8168009/
https://www.ncbi.nlm.nih.gov/pubmed/34059157
http://dx.doi.org/10.1186/s40780-021-00204-z

Ejemplares similares